While the emergence of mTOR inhibitors as a treatment for TSC has revolutionized the targeted therapeutic approach to TSC in general, limitations in efficacy for neurological symptoms of TSC and systemic side effects of mTOR inhibitors indicate that additional directed strategies to treating neurological manifestations of TSC. Here, MTOR is linked to tuberous sclerosis.